{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:29:38Z","timestamp":1794450578187,"version":"4.9.1"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,9]]},"abstract":"<jats:p>Migraine is a complex and often debilitating neurological disease that affects more than 1 billion people worldwide. It is characterized by moderate-to-intense, throbbing headache attacks that are worsened by activity and is associated with nausea, vomiting, and sensitivity to light and sound. Migraine, ranked the second leading cause of years lived with disability by the World Health Organization, can diminish patients\u2019 quality of life and bring significant personal and economic burden. Furthermore, migraine patients with a history of acute medication overuse (AMO) or psychiatric comorbidities, such as depression or anxiety, may experience even greater impairment and burden, and their migraine may be more difficult-to-treat. Appropriate treatment of migraine is essential to reduce this burden and improve patient outcomes, especially for those with AMO or psychiatric comorbidities. There are several available preventive treatment options for migraine, though many of these are not migraine-specific and may have limited efficacy and\/or poor tolerability. The calcitonin gene-related peptide pathway plays a key role in the pathophysiology of migraine, and monoclonal antibodies that target the calcitonin gene-related peptide pathway have been developed as specific preventive treatments for migraine. Four of these monoclonal antibodies have been approved for the preventive treatment of migraine after demonstrating favorable safety and efficacy profiles. These treatments offer substantial benefits for migraine patients, including those with AMO or common psychiatric comorbidities, by reducing monthly headache days and migraine days, days of acute medication use, and disability measures, as well as improving quality of life.<\/jats:p>","DOI":"10.1097\/md.0000000000033874","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:12:06Z","timestamp":1686319926000},"page":"e33874","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4540-4485","authenticated-orcid":false,"given":"Christopher","family":"Rhyne","sequence":"first","affiliation":[{"name":"Diamond Headache Clinic, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Seminerio","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Carr","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda J.","family":"Krasenbaum","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","article-title":"Migraine: multiple processes, complex pathophysiology.","volume":"35","author":"Burstein","year":"2015","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"R2-20250504","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.pain.2013.07.021","article-title":"Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain.","volume":"154","author":"Noseda","year":"2013","journal-title":"Pain"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders.","volume":"38","author":"Arnold","year":"2018","journal-title":"Cephalalgia"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","article-title":"Burden of neurological disorders across the US From 1990-2017: a global burden of disease study.","volume":"78","author":"Feigin","year":"2021","journal-title":"JAMA Neurol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019.","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/head.13275","article-title":"Direct and indirect healthcare resource utilization and costs among migraine patients in the United States.","volume":"58","author":"Bonafede","year":"2018","journal-title":"Headache"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.amepre.2017.07.019","article-title":"Prevalence and medical costs of chronic diseases among adult medicaid beneficiaries.","volume":"53","author":"Chapel","year":"2017","journal-title":"Am J Prev Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","article-title":"Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study.","volume":"21","author":"Buse","year":"2020","journal-title":"J Headache Pain"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/da.23063","article-title":"Humanistic and economic burden of depression and anxiety among adults with migraine: as systematic review.","volume":"37","author":"Alwhaibi","year":"2020","journal-title":"Depress Anxiety"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","article-title":"Medication overuse and headache burden: results from the CaMEO study.","volume":"11","author":"Schwedt","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"R11-20250504","first-page":"206","article-title":"Health care utilization and costs in patients with migraine who have failed previous preventive treatments.","volume":"11","author":"Newman","year":"2021","journal-title":"Neurol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"658697","DOI":"10.3389\/fneur.2021.658697","article-title":"Healthcare expenditures associated with comorbid anxiety and depression among adults with migraine.","volume":"12","author":"Alwhaibi","year":"2021","journal-title":"Front Neurol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1017\/S1462399411002067","article-title":"Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.","volume":"13","author":"Raddant","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): a new target for migraine.","volume":"55","author":"Russo","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","article-title":"Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life.","volume":"84","author":"Buse","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/head.13914","article-title":"The effect of psychiatric comorbidities on headache\u2010related disability in migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1212\/01.WNL.0000058907.41080.54","article-title":"Comorbidity of migraine and depression: investigating potential etiology and prognosis.","volume":"60","author":"Breslau","year":"2003","journal-title":"Neurology"},{"issue":"Suppl 3","key":"R18-20250504","first-page":"S756","article-title":"Burden of comorbid depression and anxiety on migraine-specific health-related quality of life in adult migraine patients in the United States.","volume":"22","author":"Lipton","year":"2019","journal-title":"Value Health"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version).","volume":"33","year":"2013","journal-title":"Cephalalgia"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","article-title":"Factors associated with acute medication overuse in people with migraine: results from the 2017 Migraine in America Symptoms and Treatment (MAST) study.","volume":"19","author":"Schwedt","year":"2018","journal-title":"J Headache Pain"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","article-title":"Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine.","volume":"84","author":"Lipton","year":"2015","journal-title":"Neurology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1526-4610.2006.00577.x","article-title":"Modifiable risk factors for migraine progression.","volume":"46","author":"Bigal","year":"2006","journal-title":"Headache"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","article-title":"Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0333102411398400","article-title":"Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review.","volume":"31","author":"Lanteri-Minet","year":"2011","journal-title":"Cephalalgia"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/head.13342","article-title":"Identifying natural subgroups of migraine based on comorbidity and concomitant condition profiles: results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice.","volume":"59","year":"2019","journal-title":"Headache"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/head.12482","article-title":"The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies.","volume":"55","author":"Burch","year":"2015","journal-title":"Headache"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.aat.2012.05.002","article-title":"Migraine diagnosis: screening items, instruments, and scales.","volume":"50","author":"Peng","year":"2012","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1177\/0333102411424212","article-title":"A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. a multicentre European and Latin American study.","volume":"31","author":"Jensen","year":"2011","journal-title":"Cephalalgia"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/01.WNL.0000078940.53438.83","article-title":"A self-administered screener for migraine in primary care: the ID Migraine validation study.","volume":"61","author":"Lipton","year":"2003","journal-title":"Neurology"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2377-10-39","article-title":"New uses of the Migraine Screen Questionnaire (MS-Q): validation in the primary care setting and ability to detect hidden migraine. MS-Q in Primary Care.","volume":"10","author":"Lainez","year":"2010","journal-title":"BMC Neurol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","article-title":"Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1).","volume":"40","author":"Martin","year":"2000","journal-title":"Headache"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s41687-019-0138-x","article-title":"Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome.","volume":"3","author":"Speck","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.genhosppsych.2017.06.006","article-title":"The prevalence of depression and the accuracy of depression screening tools in migraine patients.","volume":"48","author":"Amoozegar","year":"2017","journal-title":"Gen Hosp Psychiatry"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2147\/NDT.S33769","article-title":"Preventive treatment in migraine and the new US guidelines.","volume":"9","author":"Estemalik","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy.","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.","volume":"307","author":"Jackson","year":"2012","journal-title":"JAMA"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/head.14053","article-title":"Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: results from the assessment of TolerabiliTy and effectiveness in MigrAINe patients using preventive treatment (ATTAIN) study.","volume":"61","author":"Kawata","year":"2021","journal-title":"Headache"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II).","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0333102421989601","article-title":"Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis.","volume":"41","author":"Drellia","year":"2021","journal-title":"Cephalalgia"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update.","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications.","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"issue":"Suppl 3","key":"R47-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/head.13379","article-title":"History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment.","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5599\/admet.4.1.276","article-title":"An overall comparison of small molecules and large biologics in ADME testing.","volume":"4","author":"Wan","year":"2016","journal-title":"Admet Dmpk"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-12-43","article-title":"What is the future of targeted therapy in rheumatology: biologics or small molecules?","volume":"12","author":"Mocsai","year":"2014","journal-title":"BMC Med"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fphar.2019.00363","article-title":"New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies.","volume":"10","author":"Scuteri","year":"2019","journal-title":"Front Pharmacol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a Phase 3 randomized trial of erenumab for episodic migraine.","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine.","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial.","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study.","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1).","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine.","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study.","volume":"40","author":"Tepper","year":"2020","journal-title":"Cephalalgia"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial.","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"R63-20250504","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s10194-021-01292-w","article-title":"Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.","volume":"22","author":"Tepper","year":"2021","journal-title":"J Headache Pain"},{"issue":"15 suppl","key":"R64-20250504","doi-asserted-by":"crossref","first-page":"P4.105","DOI":"10.1212\/WNL.90.15_supplement.P4.105","article-title":"Efficacy of erenumab for the treatment of patients with episodic migraine with depression and\/or anxiety.","volume":"90","author":"Tepper","year":"2018","journal-title":"Neurology"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","article-title":"Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.","volume":"43","author":"Pensato","year":"2022","journal-title":"Neurol Sci"},{"key":"R66-20250504","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","article-title":"Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study.","volume":"42","author":"Cainazzo","year":"2021","journal-title":"Neurol Sci"},{"issue":"Suppl 2","key":"R67-20250504","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","article-title":"Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study.","volume":"41","author":"Schiano di Cola","year":"2020","journal-title":"Neurol Sci"},{"key":"R68-20250504","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1007\/s10072-022-06265-8","article-title":"Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.","volume":"43","author":"Curone","year":"2022","journal-title":"Neurol Sci"},{"key":"R69-20250504","doi-asserted-by":"crossref","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study.","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"R70-20250504","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"R71-20250504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.","volume":"21","author":"Silberstein","year":"2020","journal-title":"J Headache Pain"},{"key":"R72-20250504","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study.","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"key":"R73-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","article-title":"Real-world effectiveness of fremanezumab treatment for patients with episodic and chronic migraine or difficult-to-treat migraine.","volume":"23","author":"Driessen","year":"2022","journal-title":"J Headache Pain"},{"key":"R74-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10194-022-01413-z","article-title":"A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.","volume":"23","author":"Krasenbaum","year":"2022","journal-title":"J Headache Pain"},{"key":"R75-20250504","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial.","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"R76-20250504","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"R77-20250504","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","article-title":"Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.","volume":"41","author":"Dodick","year":"2020","journal-title":"Cephalalgia"},{"key":"R78-20250504","first-page":"645","article-title":"Changes in acute headache medication use and health care resource utilization: results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).","volume":"28","author":"Ambrosini","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"R79-20250504","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/head.13970","article-title":"Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and\/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies.","volume":"60","author":"Smitherman","year":"2020","journal-title":"Headache"},{"key":"R80-20250504","first-page":"30517","article-title":"Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study.","volume":"S0149-2918","author":"Smith","year":"2020","journal-title":"Clin Ther"},{"key":"R81-20250504","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"R82-20250504","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2.","volume":"61","author":"Diener","year":"2021","journal-title":"Headache"},{"key":"R83-20250504","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/head.14206","article-title":"Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.","volume":"61","author":"Marmura","year":"2021","journal-title":"Headache"},{"key":"R84-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/head.14434","article-title":"Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: subgroup analysis of the randomized PROMISE-2 trial.","volume":"63","author":"Starling","year":"2023","journal-title":"Headache"},{"issue":"Supplement 15","key":"R86-20250504","doi-asserted-by":"crossref","first-page":"S17.005","DOI":"10.1212\/WNL.92.15_supplement.S17.005","article-title":"Fremanezumab cardiovascular and cerebrovascular safety profile: pooled data from placebo-controlled and long-term studies (S17.005).","volume":"92","author":"Ning","year":"2019","journal-title":"Neurology"},{"key":"R87-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/head.13684","article-title":"Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.","volume":"60","author":"Oakes","year":"2020","journal-title":"Headache"},{"key":"R88-20250504","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","article-title":"Vascular safety of erenumab for migraine prevention.","volume":"94","author":"Kudrow","year":"2020","journal-title":"Neurology"},{"issue":"8 Suppl","key":"R91-20250504","first-page":"S227","article-title":"Will the newer oral MS agents be welcomed by managed care organizations?","volume":"16","author":"Lipsy","year":"2010","journal-title":"Am J Manag Care"},{"key":"R92-20250504","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40271-020-00417-8","article-title":"Qualitative thematic analysis of social media data to assess perceptions of route of administration for antiretroviral treatment among people living with HIV.","volume":"13","author":"Matza","year":"2020","journal-title":"Patient"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:06:13Z","timestamp":1746324373000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":85,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033874","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}